Nebenwirkungen · Kisplyx
Kisplyx 4 mg hard capsules Kisplyx 10 mg hard capsules · Abschnitt 4.8 · PDF-Seite 18
HOS-225031 · Präparat HOS-217386
In the pooled RCC population treated with lenvatinib and everolimus, haemorrhage events were reported in 28.6% of patients (3.2% were Grade ≥3). In patients where data on individual drug modifications were collected, 4.9% of patients with haemorrhage events had dose modifications of lenvatinib (4.2% interruption and 0.8% reduction) and led to permanent treatment discontinuation in 0.6% of patients. The most commonly reported haemorrhage events in the lenvatinib plus everolimus-treated group were epistaxis (19.4%) and haematuria (4.2%). The median time to onset of haemorrhage events in lenvatinib plus everolimus treated patients was 1.9 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-26T17:24:00Z · SHA-256 a44a00845e1c56c73ff53a9371d99e0ff78be7df90f4e83eb5595124e9e6b142 · Passage 68d3ecab3607cd72c2cfc7145c0044c5e8b2a25ba5eb07c596affcd37a806b91 · Zeichen 26917–27568 im Abschnitt